NEWS

PRESS RELEASE

Microvention celebrates grand opening of new worldwide innovation center...

ALISO VIEJO, CA - MicroVention, a wholly owned  subsidiary of Terumo Corporation and a global neurovascular company, today announced that the Grand Opening of its New Innovation Center was held on Monday, September 25. The opening of the new facility, located in the heart of the Summit Office Campus, also signifies the Company's official return to Aliso Viejo: MicroVention was founded there in 1997, originally occupying buildings very close to the new location and is also commemorating their 20 year anniversary as a Company.

PRESS RELEASE

Johnson & Johnson Medical Devices Companies announces new neurovascular...

Colorado Springs, Co. – Johnson & Johnson Medical Devices Companies* today introduced CERENOVUS,** its new neurovascular business, at the Society of NeuroInterventional Surgery (SNIS) 14th Annual Meeting. CERENOVUS, a name derived from the Latin words for ‘new’ and ‘brain’, will focus on delivering innovative therapies for hemorrhagic and ischemic stroke patients.

PRESS RELEASE

phenox as Silver Sponsor of LINNC 2017

On June 13-15, the 20th “Live International Neuroradiology and Neurosurgery Course” took place. Specialists of neuroradiology met at the Carrousel du Louvre in Paris, to discuss live cases which were presented from all over the world. phenox has sponsored the LINNC for years. This year was the first time phenox was a silver sponsor of the meeting and was present with a booth, a training area as well as its own symposium.

PRESS RELEASE

Codman Neuro announces acquisition of Neuravi Limited to accelerate inno...

 Second acquisition in months demonstrates commitment to addressing unmet needs in stroke

PRESS RELEASE

PRESS RELEASE

Stryker announces an early stop to enrollment in the DAWN™ Trial due to...

Kalamazoo, Michigan, USA – March 07, 2017 – Stryker announced an early end to patient enrollment in the DAWN Trial, a clinical study designed to compare mechanical thrombectomy with the Trevo® Retriever plus medical therapy against medical therapy alone when initiated within six to 24 hours after time last known well. The independent Data Safety Monitoring Board (DSMB) recommended stopping study enrollment based on a pre-planned interim review of data from the first 200 patients, which concluded that multiple pre-specified stopping criteria were met. A final analysis of the data will be conducted upon completion of the remaining patient follow-up.

PRESS RELEASE

Independent study supports use of Penumbra aspiration as frontline throm...

Results of ASTER study presented at International Stroke Conference